Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

eRaDicate Innovative ligands for nuclear receptors to eradicate cancer relapse.

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
23 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119427

What the project is doing

In the project's own words, from its summary on CORDIS.

The aim of the “eRaDicate” international, multidisciplinary, and intersectoral cancer drug research and development programme is to empower 10 young scientists to become specialists in cancer research and drug development, while developing new therapies against cancer stem cell-driven relapse and metastasis. Nuclear receptors, such as retinoic acid receptor (RAR) and vitamin D receptor (VDR), play key roles in many hallmarks of cancer and constitute effective targets for modern cancer therapy.

To address the EU priority “Mission Cancer”, we will 1) test the anti-cancer activity of RAR and VDR targeting compounds; 2) design and synthesise a highly innovative dual action hybrid compound acting simultaneously as RARγ antagonist and VDR agonist; 3) devise pre-formulation strategies for our compounds; 4) and develop a novel, deep learning-based cancer analysis and diagnostics method. We will test how our RAR and VDR-targeting compounds affect stemness and metastatic potential in leukaemia, breast, prostate, colorectal, and ovarian cancer.

In parallel, we will assess if the pan-RAR antagonist is effective against chemotherapy-induced neutropenia. For the development of the RAR and VDR targeting compounds into administrable medicines, ready for eventual commercialisation, we will develop pre-formulation strategies. We will generate a novel and highly innovative label-free image analysis method based on histoplasmonic cytometry. The project will have lasting scientific, economic, and societal impact.

In order to be prepared for a wide spectrum of career opportunities, we will train the doctoral candidates (DCs) not only to perform original and independent research on an internationally competitive level, but also endow them with creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives. Our consortium consists of 8 academic and 1 industrial beneficiary, as well as 12 associated partners to provide training and secondments.

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator
Biolution GmbHWienAustriaAssociatedpartner
Danube Private University GmbHKrems-SteinAustriaAssociatedpartner
Karl Landsteiner Privatuniversitat Fur Gesundheitswissenschaften GmbHKrems an der DonauAustriaAssociatedpartner
Mag. Franz TettingerAustriaAssociatedpartner
Tissuegnostics GmbHWienAustriaParticipant
La Trobe UniversityLa Trobe UniversityAustraliaAssociatedpartner
Queensland University of Technology - Qld QutBrisbaneAustraliaAssociatedpartner
The Governing Council of the University of TorontoTorontoCanadaAssociatedpartner
Physiolution GmbHGreifswaldGermanyAssociatedpartner
Universidad De Santiago De CompostelaSantiago De CompostelaSpainParticipant
Janssen Sciences Ireland UCCorkIrelandAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Ben-Gurion University of the NegevBeer ShevaIsraelParticipant
Shaare Zedek Medical CenterJerusalemIsraelAssociatedpartner
Wannaboo S.r.l.ValdagnoItalyAssociatedpartner
Envigo Rms BVHorstNetherlandsAssociatedpartner
Pikralida sp. z o.o.PoznańPolandAssociatedpartner
Selvita S.A.KrakowPolandAssociatedpartner
Uniwersytet WarszawskiWarszawaPolandParticipant
Uniwersytet WroclawskiWroclawPolandParticipant
Warszawski Uniwersytet MedycznyWarszawaPolandParticipant
The University of BirminghamBirminghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI